Sai Parenteral's IPO
Sai Parenteral's IPO — date, price band, lot size & details 2026
Sai Parenteral's listed on 2 Apr 2026 at ₹400, 2% above the ₹392 issue price.
Sai Parenteral’s IPO is scheduled to open from 24 March to 27 March 2026, aiming to raise funds for expansion and working capital needs. Founded in 1998, the company operates in the pharmaceutical sector, focusing on manufacturing injectable medicines. Its business model centres on contract manufacturing and supplying hospitals and healthcare institutions. Sai Parenteral has a strong presence across India, particularly in western and northern regions, with growing distribution networks.
Stock price
Sai Parenteral's is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 23 October.
- Open 24 Mar 2026
- Close 27 Mar 2026
- Allotment 30 Mar 2026
- Refund/credit 01 Apr 2026
- Listing 02 Apr 2026
Issue summary
The terms of the offer, as filed.
| IPO Dates | 24 to 27 Mar, 2026 |
|---|---|
| Price Band | ₹372 – ₹392 |
| Face Value | ₹5 |
| Lot Size | 38 Shares |
| Issue Size | ₹409 Cr |
| Sale Type | OFS |
| Listing On | BSE, NSE |
| Registrar | Bigshare Services Private Limited |
| Min Investment | ₹ 14,896 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 38 shares at the ₹392 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 38 | ₹14,896 |
| Retail (max) | 13 | 494 | ₹1,93,648 |
| S-HNI (min) | 14 | 532 | ₹2,08,544 |
| S-HNI (max) | 67 | 2,546 | ₹9,98,032 |
| B-HNI (min) | 68 | 2,584 | ₹10,12,928 |
Three years of numbers
All figures in ₹ crore, as reported in the Sai Parenteral's offer document.
| Metric | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 89.43 | 163.74 | 155.18 |
| EBITDA | 16.24 | 39.44 | 31.70 |
| Net Profit | 7.76 | 14.43 | 8.42 |
| Debt | 76.07 | 93.95 | 118.79 |
| Assets | 376.24 | 272.39 | 268.10 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Sai Parenteral's RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Sai Parenteral's IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Post-Issue |
|---|---|
| EPS (₹) | ₹5.43 |
| P/E Ratio (x) | 72.19 |
| Market Cap at Offer Price (₹ Cr) | ₹560.21 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹392 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹209.12 Cr of the issue is earmarked to named objects.
Sai Parenteral's IPO Anchor Investors
5 anchor investors across 5 fund houses committed ₹122.64 Cr a day before the issue opened.
| Anchor Investor | Fund House | Shares | Amount (₹ Cr) | % of Anchor Book |
|---|---|---|---|---|
| Kotak Life Sciences Fund I | Kotak | 765,282 | 30.00 | 24.46% |
| India Emerging Giants Fund Ltd. | India Emerging | 296,849 | 11.64 | 9.49% |
| Morgan Stanley Asia (Singapore) Pte. | Morgan Stanley | 382,650 | 15.00 | 12.23% |
| Kotak Mahindra Life Insurance Co.ltd. | Kotak Life Insurance | 765,320 | 30.00 | 24.46% |
| Quant Momentum Fund | Quant Mutual Fund | 918,384 | 36.00 | 29.36% |
| Total anchor allocation | 122.64 | |||
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
The company’s product portfolio primarily includes injectable formulations such as antibiotics, analgesics, and other therapeutic drugs used in hospitals and healthcare institutions. It follows a business model that combines contract manufacturing and direct marketing, enabling it to serve both institutional buyers and third-party clients. Sai Parenteral emphasises quality control, modern manufacturing facilities, and adherence to regulatory standards, which supports its long-term growth. By maintaining strong relationships with clients and focusing on operational efficiency, the company aims to expand its footprint in the competitive pharmaceutical sector.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
+91 79979 91301
The bankers & the filings
Who is running the book, and the documents this page is built from.
Sai Parenteral's IPO Documents
Read the filings this page is built from.
Company contact
Frequently asked
What is the GMP of Sai Parenteral's?
The current Grey Market Premium is ₹00.
What is the Sai Parenteral's IPO price band?
₹372 to ₹392, on a face value of ₹5.
When is the allotment?
The basis of allotment is 30 March 2026, with listing on 2 April 2026.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — Bigshare Services Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
